Grasustek (pegfilgrastim)

Leave a review
Bookmark
Share
Report
prev
next

Indicaton

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy

Therapeutic indications

Oncology

Type of product

Peptide

Table

Phase

Marketed
Partnering status

Partnered
Partner

USV

You may also be interested in

3D CoSeedis in chip Assays

Preclinical 3D Study models for oncology and neurology.

Marketed

F2i

F2i is a first-in-class, non-kinase, protein-protein interaction inhibitor of aberrant fibroblast growth factor signalling pathway in invasive cancers

Discovery

MV-004

MV-004 is an orally available recombinant bacterial enzyme acting in the small intesine to adaptively modulate microbiota function during cancer immunotherapy. MV004 has been conceived to convert the majority of patients with solid tumors non-responding to immune checkpoint blockade (ICB) to responders.

Discovery

Grasustek (pegfilgrastim)

Indicaton

Therapeutic indications

Type of product

Company

Table

You may also be interested in

3D CoSeedis in chip Assays

F2i

MV-004